Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

June 30, 2020 09:07 AM EDTUpdated 10:20 AM

Positive Covid-19 vaccine data? New mouse study? OWS inclusion? Yep, but somehow, the usual tidbits from Inovio backfire

You don’t go more than 40 years in biotech without ever getting a product to market unless you can learn the art of writing a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

Summit’s disappointing survival readout raises stakes for full data

Summit says bispecific misses overall survival in closely-watched lung cancer study

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop

As a challenging first half nears a close, biopharma uncertainty persists

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation